Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

X ray of arm fracture with red pain point. Broken hand with open type of fracture. Human skeleton anatomy concept. Medical banner for clinic or hospital. Vector

Phase III

Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures

With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming Angelman syndrome readout.

January 2, 2026

2 min read

Annalee Armstrong

Business growth or increase in professional income, business operations, investment profits or interest on savings, increase in interest rates, businessman holding gold coins forming a growing arrow symbol.

Drug pricing

Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers reportedly plan to raise the U.S. prices of at least 350 branded medications.

January 2, 2026

2 min read

Nick Paul Taylor

whale watching boat in Iceland, group of people look at whale

Approvals

Vanda Ends 40-Year Motion Sickness Drug Drought With FDA Approval for Nereus

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are dissatisfied with existing treatments.

January 2, 2026

3 min read

Nick Paul Taylor

Recession arrow, Graph showing business decline on led screen

Complete response letters

FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices

Both companies received agency requests for more evidence of the effectiveness of their therapies.

January 2, 2026

2 min read

Nick Paul Taylor

Big fish eats small, takeover of the company. Art collage.

Mergers & acquisitions

Five Biggest Biopharma Takeovers of 2025

Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.

January 2, 2026

8 min read

Tristan Manalac

Observation, search for opportunity, curiosity or surveillance, inspect or discover new business, job search or hr finding candidate concept, curious businessman look through binoculars with big eyes.

Alzheimer’s disease

In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.

January 2, 2026

5 min read

Annalee Armstrong

Diet pills and bottle of diet supplements with measuring tape

GLP-1

Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race

Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.

December 23, 2025

2 min read

Nick Paul Taylor

vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake

Neuroscience

Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial

Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.

December 23, 2025

2 min read

Nick Paul Taylor